AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2134648
Drug: Ultrasound and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound and preoperative treatment of the neck area
Trial: 23530672
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without explicit pharmacotherapy curriculum)
Trial: 18042559
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of ropivacaine 2 mg ml(‐1), sufentanil 0.5 microg ml(‐1), clonidine 3 microg ml(‐1), and S(+)‐ketamine 0.25 mg ml(‐1) before incision (Group 1)
Trial: 18042559
Drug: Saline before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline before operation, study solution started at the end of surgery (Group 2)
Trial: 21070569
Drug: Transdermal oxybutynin
RxNorm normalized name: oxybutynin Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oxybutynin
Trial: 12964892
Drug: Oral oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxybutynin or oral tolterodine
Trial: 1300436
Drug: Furosemide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (mean dose 110 mg) intravenously 30 min prior to contrast injection
Trial: 29704641
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP (>3 mg/l ≤ 10 mg/l) as an isolated reading
Trial: 373393
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg daily)
Trial: 23176887
Drug: Salbutamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (2 puffs of 100 μg)
Trial: 18342964
Drug: 7-days-a-week postoperative
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-days-a-week postoperative continuous irradiation (p-CAIR) in oropharynx/oral cavity subset
Trial: 18342964
Drug: 5-days-a-week postoperative
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-days-a-week postoperative radiotherapy (CF) in oropharynx/oral cavity subset
Trial: 7805271
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy for patients with moderate stroke with stenosis <50%, not on aspirin
Trial: 7805271
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy for patients with single TIA, <50% stenosis, not on aspirin
Trial: 7805271
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy for high-risk patients with multiple TIAs, not on aspirin, stenosis <50%
Trial: 7805271
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy for high-risk patients, mild or moderate stroke, stenosis <50%, not on aspirin
Trial: 1674825
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg/ml inhaled
Trial: 1674825
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg/ml inhaled
Trial: 30668423
Drug: Extract mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract mixture of Andrographis paniculata and Syzygium polyanthum at a dose of 900 mg/day for 8 weeks
Trial: 11826593
Drug: SF6 echocontrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SF6 echocontrast agent (SonoVue) 0.6 mL
Trial: 11826593
Drug: SF6 echocontrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SF6 echocontrast agent (SonoVue) 1.2 mL
Trial: 10084096
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg min‐1 propofol
Trial: 1706012
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem 240 mg
Trial: 1706015
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem 300 mg
Trial: 1706012
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem 360 mg
Trial: 26715213
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg (EFV400)
Trial: 26715213
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg (EFV600)
Trial: 21256786
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene with chlorhexidine (GS)
Trial: 21256786
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene with electric dental brush (GR)
Trial: 2915238
Drug: One-day cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day cisplatin, doxorubicin, and cyclophosphamide (PAC-I) chemotherapy
Trial: 2915238
Drug: Five-day PAC
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day PAC (PAC-V) chemotherapy
Trial: 27696678
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation for 15 minutes daily for 90 days
Trial: 21808851
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg, 3 times/day)
Trial: 15803287
Drug: Combined mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mitoxantrone and methylprednisolone therapy
Trial: 7549222
Drug: Zatebradine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatebradine (10 mg)
Trial: 9609523
Drug: Oral pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate 300 mg daily
Trial: 7974588
Drug: CC method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC method
Trial: 29306223
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate intake
Trial: 25616519
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (4 g/kg/d)
Trial: 19469885
Drug: Magnesium carbonate/calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium carbonate/calcium carbonate (elemental Mg: 86 mg/elemental Ca 100 mg) administered as phosphate binder for 18 months
Trial: 19469885
Drug: Magnesium carbonate/calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium carbonate/calcium carbonate (elemental Mg: 86 mg/elemental Ca 100 mg)
Trial: 24923372
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg)
Trial: 11679451
Drug: OGTT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT + F (75 g glucose + 7.5 g fructose)
Trial: 7834919
Drug: Lactate-buffered hemofiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-buffered hemofiltration (lactate concentration 34-44.5 mmol/l)
Trial: 7834919
Drug: Type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type II bicarbonate-buffered fluid (bicarbonate concentration 39.7 mmol/l)
Trial: 7834919
Drug: Type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type I bicarbonate-buffered fluid (bicarbonate concentration 31.4 mmol/l)
Trial: 7834919
Drug: Type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type II bicarbonate fluid (bicarbonate concentration 39.7 mmol/l)
Trial: 29544063
Drug: l-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine supplementation
Trial: 16708408
Drug: Plantago ovata
RxNorm normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plantago ovata (2 sachets daily of 3.26 g for 20 days)
Trial: 10781391
Drug: Selenomethionine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenomethionine (50 microg of Se daily for 28 days)
Trial: 10781391
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Sodium selenite and Selenomethionine)
Trial: 8748408
Drug: Dextran 40-based
RxNorm normalized name: Dextran 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 40-based preservation solution (Dex-PS)
Trial: 1407917
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intravaginal PGE2 tablets
Trial: 1407917
Drug: Placebo intravaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravaginal tablets (Control)
Trial: 2996161
Drug: Both combinations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both combinations of antibiotics
Trial: 31688579
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.1 mg/d) + 200 mg progesterone (12 d every 3 mo)
Trial: 30571235
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment (target systolic blood pressure <120 mm Hg)
Trial: 30571235
Drug: Standard antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antihypertensive treatment (target systolic blood pressure <140 mm Hg)
Trial: 30571235
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (intensive and standard)
Trial: 9177952
Drug: Moclobemide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (both doses)
Trial: 12145765
Drug: Glucose (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (75 g)
Trial: 3518072
Drug: butorphanol 2
RxNorm normalized name: butorphanol 2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: butorphanol 2 mg
Trial: 26099
Drug: Dipotassium chlorazepate
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipotassium chlorazepate divided daily dose (5 + 5 + 10 mg)
Trial: 23365149
Drug: Oral risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate (RIS)
Trial: 23146820
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg synthetic oral THC
Trial: 23146820
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg synthetic oral THC
Trial: 21078841
Drug: Low-dose Sativex
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Sativex (5.4 mg THC and 5.0 mg CBD)
Trial: 21078841
Drug: High-dose Sativex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Sativex (16.2 mg THC and 15.0 mg CBD)
Trial: 21078841
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral THC
Trial: 19608695
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of rotigotine (1.2 mg over 12 hours)
Trial: 19608695
Drug: Transdermal application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal application of rotigotine (4.5 mg via 10-cm² patch for 24 hours)
Trial: 11099054
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year
Trial: 11099054
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy and long-term omeprazole
Trial: 10430396
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy
Trial: 3529362
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg, given twice daily for 2 days
Trial: 3529362
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given twice daily for 2 days
Trial: 30563582
Drug: Long-term continuous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term continuous antipsychotic treatment
Trial: 30563582
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of antipsychotics
Trial: 22071059
Drug: 10 L
RxNorm normalized name: PEG-10 LANOLIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 L of oxygen by nonrebreather mask during and for 2 hours after cesarean delivery
Trial: 22071059
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of oxygen by nasal cannula during cesarean delivery only (standard care)
Trial: 9155286
Drug: Detailed psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detailed psychological preparation and support
Trial: 9155286
Drug: Standard informal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard informal preparation
Trial: 7960973
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment including a new 'opponens roll' maneuver and self-stretching
Trial: 3068344
Drug: Captopril (12.5‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5‐50 mg twice a day)
Trial: 28617807
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment failure
Trial: 3674849
Drug: Aminoglycoside serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside serum levels, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence of bacteremia, shock, liver cirrhosis, dehydration, previous otic pathology or renal failure, and development of renal toxicity
Trial: 25182045
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy for 6 months
Trial: 20022872
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow stem cells (BMSCs) administered into infarct-related artery (IRA) at 4-6 days after primary PCI
Trial: 11800181
Drug: Self-control training
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-control training procedure with reinforcer immediacy competing with another influential dimension (e.g., RvI or QvI)
Trial: 23043578
Drug: Postoperative conformal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide
Trial: 31056733
Drug: cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilostazol (200 mg/day)
Trial: 21921460
Drug: aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (81 mg/day)
Trial: 8729587
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg/day and bezafibrate 400 mg/day
Trial: 2658640
Drug: Ceftazidime 1
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1 g
Trial: 1816189
Drug: Ceftazidime 3
RxNorm normalized name: ceftazidime 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3 g
Trial: 10672977
Drug: labetalol 100
RxNorm normalized name: HCTZ 25/LABETALOL 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 100 mg
Trial: 7049710
Drug: chlorthalidone 10
RxNorm normalized name: chlorthalidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone 10 mg
Trial: 31668592
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg orally once daily for 12 weeks
Trial: 22166255
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care (n=40) with traditional DMARDs (no prednisone or biologics).
Trial: 16306499
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of salbutamol and fluticasone
Trial: 30585337
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1200 mg plus 400 mg vitamin E
Trial: 30585337
Drug: Placebo (starch)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch) plus 400 mg vitamin E
Trial: 22880108
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aerobic and resistance exercise
Trial: 19379588
Drug: CAG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAG regimen (aclarubicin/Ara-C, G-CSF)
Trial: 7802307
Drug: Clonidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (75 micrograms) and Morphine (0.5 mg)
Trial: 7802307
Drug: Morphine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.5 mg)
Trial: 7001044
Drug: Povidone-iodine gel
RxNorm normalized name: povidone-iodine gel 10 % Medicated Pad
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine gel
Trial: 24548259
Drug: Sugar-sweetened beverages
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverages (SSB) consumption (100 g day(-1))
Trial: 24548259
Drug: Substitution of
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution of 100 g of SSB by 100 g of water or diet drink
Trial: 17966760
Drug: Thyme-primrose combination
RxNorm normalized name: THYME
DrugBank: Thyme (DB10983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyme-primrose combination
Trial: 17966760
Drug: Thyme-primrose combination
RxNorm normalized name: THYME
DrugBank: Thyme (DB10983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyme-primrose combination and Placebo
Trial: 26012585
Drug: STEEP-b plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEEP-b plus treatment as usual (TAU)
Trial: 7759676
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and cognitive-behavioral therapy methods
Trial: 7759676
Drug: Specific, focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific, focused therapy methods
Trial: 2539203
Drug: Efamol (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efamol (evening primrose oil containing gamma-linolenic acid, with vitamin E as preservative) - 8 capsules per day
Trial: 25757593
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d pure hesperidin supplement
Trial: 23497761
Drug: Fentanyl Sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl Sublingual Spray (FSS) 400 μg
Trial: 23497761
Drug: Intravenous Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Fentanyl Citrate 100 μg
Trial: 9252801
Drug: Tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (200 mg)
Trial: 11593078
Drug: Dextroamphetamine sulfate,
RxNorm normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate, sustained-release capsules (30 to 60 mg)
Trial: 30180273
Drug: CaCO3 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 1200 mg/day with 10,000 IU vitamin D3/day
Trial: 30180273
Drug: CaCO3 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 1200 mg/day with 600 IU vitamin D3/day
Trial: 26654135
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (n = 85)
Trial: 19150495
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil containing 3.7 g/day n‐3 polyunsaturated fatty acid (n‐3PUFA)
Trial: 19150495
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil containing 3.7 g/day n‐3PUFA
Trial: 8207699
Drug: Sandimmune Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune Neoral (180 mg)
Trial: 2914336
Drug: 3 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml.kg‐1 of apple juice given 2.6 +/‐ 0.4 hours preoperatively
Trial: 31575326
Drug: Tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)
Trial: 31575326
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)